
Brief intro:
- Author: Dirk Mossmann, Christoph Müller, Sujin Park, Brendan Ryback, Marco Colombi, Nathalie Ritter, Diana Weißenberger, Eva Dazert, Mairene Coto-Llerena, Sandro Nuciforo, Lauriane Blukacz, Caner Ercan, Veronica Jimenez, Salvatore Piscuoglio, Fatima Bosch, Luigi M. Terracciano, Uwe Sauer, Markus H. Heim, Michael N. Hall
- Journal: Cell
- Doi: https://www.doi.org/10.1016/j.cell.2023.09.011
- Publication Date: 2023 Oct 6
Products/Services used in the paper
Quotation shows PackGene:For knockdown of Asns and Rbm39 following AAV particles were purchased from Packgene (USA): AAV-DJ[ssAAV.ALB.EGFP.miR30shRNA(mScramble). WPRE.SV40pA] (AAV-shCtrl), AAV-DJ[ssAAV.ALB.EGFP.miR30shRNA(mASNS).WPRE.SV40pA] (AAV-shAsns), AAV-DJ[ssAAV.ALB.EGFP.miR30shRNA(mRBM39).WPRE.SV40pA] (AAV-shRbm39). 5x10^11 GC in PBS were injected per mouse.
Research Field:Liver Cancer
AAV Serotype:AAV.DJ
Targeted organ:LIver
Animal or cell line strain:mouse
Abstract
Metabolic reprogramming is a hallmark of cancer. However, mechanisms underlying metabolic reprogramming and how altered metabolism in turn enhances tumorigenicity are poorly understood. Here, we report that arginine levels are elevated in murine and patient hepatocellular carcinoma (HCC), despite reduced expression of arginine synthesis genes. Tumor cells accumulate high levels of arginine due to increased uptake and reduced arginine-to-polyamine conversion. Importantly, the high levels of arginine promote tumor formation via further metabolic reprogramming, including changes in glucose, amino acid, nucleotide, and fatty acid metabolism. Mechanistically, arginine binds RNA-binding motif protein 39 (RBM39) to control expression of metabolic genes. RBM39-mediated upregulation of asparagine synthesis leads to enhanced arginine uptake, creating a positive feedback loop to sustain high arginine levels and oncogenic metabolism. Thus, arginine is a second messenger-like molecule that reprograms metabolism to promote tumor growth.
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
